ES2340450T3 - Un suministro de arginina para el calentamiento de tejidos frios/enfriados. - Google Patents
Un suministro de arginina para el calentamiento de tejidos frios/enfriados. Download PDFInfo
- Publication number
- ES2340450T3 ES2340450T3 ES98946099T ES98946099T ES2340450T3 ES 2340450 T3 ES2340450 T3 ES 2340450T3 ES 98946099 T ES98946099 T ES 98946099T ES 98946099 T ES98946099 T ES 98946099T ES 2340450 T3 ES2340450 T3 ES 2340450T3
- Authority
- ES
- Spain
- Prior art keywords
- arginine
- composition
- topical
- cold
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229930064664 L-arginine Natural products 0.000 claims abstract description 28
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 28
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 28
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 230000000699 topical effect Effects 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 230000017531 blood circulation Effects 0.000 claims description 7
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- RVEWUBJVAHOGKA-WOYAITHZSA-N Arginine glutamate Chemical compound OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N RVEWUBJVAHOGKA-WOYAITHZSA-N 0.000 claims description 2
- 150000008535 L-arginines Chemical class 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- IAHBIMWHYUOIOH-UHFFFAOYSA-N vanadium hydrochloride Chemical compound Cl.[V] IAHBIMWHYUOIOH-UHFFFAOYSA-N 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 238000010792 warming Methods 0.000 abstract description 5
- 201000001881 impotence Diseases 0.000 abstract description 2
- 238000013508 migration Methods 0.000 abstract description 2
- 230000005012 migration Effects 0.000 abstract description 2
- 208000005230 Leg Ulcer Diseases 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 210000004761 scalp Anatomy 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 14
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 13
- 239000004475 Arginine Substances 0.000 description 12
- 235000009697 arginine Nutrition 0.000 description 12
- 229960003121 arginine Drugs 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 5
- 235000002566 Capsicum Nutrition 0.000 description 5
- 239000006002 Pepper Substances 0.000 description 5
- 241000722363 Piper Species 0.000 description 5
- 235000016761 Piper aduncum Nutrition 0.000 description 5
- 235000017804 Piper guineense Nutrition 0.000 description 5
- 235000008184 Piper nigrum Nutrition 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 150000001483 arginine derivatives Chemical class 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 239000008601 oleoresin Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010034568 Peripheral coldness Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- -1 e.g. Chemical compound 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US932595 | 1997-09-17 | ||
| US08/932,595 US5922332A (en) | 1997-09-17 | 1997-09-17 | Topical delivery of arginine to overcome pain |
| US932227 | 1997-09-17 | ||
| US08/936,188 US5895658A (en) | 1997-09-17 | 1997-09-17 | Topical delivery of L-arginine to cause tissue warming |
| US08/936,189 US6207713B1 (en) | 1997-09-17 | 1997-09-17 | Topical and oral delivery of arginine to cause beneficial effects |
| US08/932,227 US7914814B2 (en) | 1997-09-17 | 1997-09-17 | Topical delivery of arginine of cause beneficial effects |
| US936189 | 1997-09-17 | ||
| US936188 | 1997-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2340450T3 true ES2340450T3 (es) | 2010-06-02 |
Family
ID=27506014
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98946099T Expired - Lifetime ES2340450T3 (es) | 1997-09-17 | 1998-09-17 | Un suministro de arginina para el calentamiento de tejidos frios/enfriados. |
| ES09014985.7T Expired - Lifetime ES2549329T3 (es) | 1997-09-17 | 1998-09-17 | Administración tópica de arginina para el tratamiento del dolor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09014985.7T Expired - Lifetime ES2549329T3 (es) | 1997-09-17 | 1998-09-17 | Administración tópica de arginina para el tratamiento del dolor |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2158907B1 (OSRAM) |
| JP (3) | JP4352114B2 (OSRAM) |
| AT (1) | ATE456302T1 (OSRAM) |
| AU (1) | AU737199B2 (OSRAM) |
| CA (1) | CA2303394C (OSRAM) |
| DE (1) | DE69841481D1 (OSRAM) |
| ES (2) | ES2340450T3 (OSRAM) |
| WO (1) | WO1999013717A1 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7914814B2 (en) | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
| US7629384B2 (en) | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US6284797B1 (en) * | 1999-04-12 | 2001-09-04 | Donald A. Rhodes | Topical treatment of pain and to promote healing |
| JP2000327560A (ja) * | 1999-05-18 | 2000-11-28 | Noevir Co Ltd | 入浴剤組成物 |
| FR2794974B1 (fr) * | 1999-06-16 | 2001-08-17 | Exsymol Sa | Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique |
| US6322493B1 (en) * | 1999-07-01 | 2001-11-27 | 40 J's Llc | Expanded clitoral sensitizing compounds with methods and apparatus for the delivery of these compounds |
| JP4681132B2 (ja) * | 2001-01-29 | 2011-05-11 | 味の素株式会社 | 一酸化窒素合成酵素産生促進剤および化粧料若しくは医薬組成物 |
| DE10113446A1 (de) * | 2001-03-19 | 2002-09-26 | Schwarzkopf Gmbh Hans | Haarbehandlungsmittel mit Betainen |
| US20050226821A1 (en) * | 2002-02-22 | 2005-10-13 | Jacob Waugh | Cosmetic formulations containing l-arginine oligomers |
| US7326717B2 (en) | 2003-05-06 | 2008-02-05 | L'oreal | Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof |
| CA2556967A1 (en) * | 2004-02-23 | 2005-09-09 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
| JP4837896B2 (ja) * | 2004-03-31 | 2011-12-14 | 焼津水産化学工業株式会社 | 精力増強剤 |
| JP2005281272A (ja) * | 2004-03-31 | 2005-10-13 | Suntory Ltd | 末梢血流改善剤 |
| JP4836044B2 (ja) * | 2004-04-02 | 2011-12-14 | 味の素株式会社 | 経口アミノ酸ニキビ治療剤 |
| JP2007532697A (ja) * | 2004-04-19 | 2007-11-15 | ストラテジック サイエンス アンド テクノロジーズ， エルエルシー | 局所的血流増大の有益な効果 |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| EP2420241A1 (en) | 2004-04-19 | 2012-02-22 | Strategic Science & Technologies, LLC | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| AU2012201048B2 (en) * | 2004-04-19 | 2013-06-06 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| JP2006169406A (ja) * | 2004-12-16 | 2006-06-29 | Fuji Latex Kk | コンドーム用水性潤滑剤および当該潤滑剤を塗布したコンドーム |
| JP2008179540A (ja) * | 2005-01-07 | 2008-08-07 | Noevir Co Ltd | 細胞分化、発生、増殖を制御する物質および該物質を含む細胞分化・発生・増殖調節剤 |
| FR2883167B1 (fr) * | 2005-03-18 | 2009-07-10 | Oreal | Composition de soin capillaire et/ou des cils contenant de l'aminexil en association avec un vasodilatateur, destinee a stimuler la croissance des cheveux et/ou des cils et/ou freiner leur chute, ses utilisations |
| EP1863431A1 (en) * | 2005-03-18 | 2007-12-12 | L'Oréal | Hair and/or eyelash care composition containing aminexil in combination with an agent for promoting the no production and uses thereof |
| US8445536B2 (en) | 2005-03-31 | 2013-05-21 | Ajinomoto Co., Inc. | Arginine-containing compositions and methods for increasing blood flow using same |
| JP5046174B2 (ja) * | 2005-03-31 | 2012-10-10 | 味の素株式会社 | アルギニン含有血流増加用組成物 |
| NZ569535A (en) | 2005-12-30 | 2011-12-22 | Revance Therapeutics Inc | Arginine heteromers for topical administration |
| WO2008089435A1 (en) * | 2007-01-18 | 2008-07-24 | Wyeth | Methods of identifying pain modulators |
| CA2700335C (en) | 2007-09-21 | 2015-12-01 | Pharmabrand S.A. | Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser |
| FR2929118B1 (fr) * | 2008-03-28 | 2010-05-07 | Oreal | Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute |
| AU2015203547B2 (en) * | 2009-06-24 | 2017-05-18 | Strategic Science & Technologies, Llc | Topical composition containing ibuprofen |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| WO2010151241A1 (en) * | 2009-06-24 | 2010-12-29 | Strategic Science & Technologies, Llc | Topical composition containing naproxen |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| RU2505291C2 (ru) | 2009-06-24 | 2014-01-27 | СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи | Топическая композиция, содержащая ибупрофен |
| JP2014501283A (ja) | 2010-12-29 | 2014-01-20 | ストラテジック サイエンス アンド テクノロジーズ， エルエルシー | アレルギーおよび他の適応症の処置のためのシステムおよび方法 |
| ES2811515T3 (es) | 2010-12-29 | 2021-03-12 | Strategic Science & Tech Llc | Tratamiento de disfunción eréctil y otras indicaciones |
| CN105307635A (zh) | 2013-03-15 | 2016-02-03 | 战略科学与技术有限责任公司 | 西地那非和其他5型磷酸二酯酶抑制剂的透皮递送 |
| JP2016513686A (ja) | 2013-03-15 | 2016-05-16 | ストラテジック サイエンス アンド テクノロジーズ， エルエルシー | フルチカゾンの経皮製剤 |
| WO2016094316A1 (en) * | 2014-12-08 | 2016-06-16 | Synaptamine, Inc. | Anti-rds compounds and method of manufacture and administration thereof to induce dopamine homeostatis |
| WO2016112201A1 (en) | 2015-01-07 | 2016-07-14 | Strategic Science & Technologies, Llc | Techniques and systems for transdermal delivery involving treatment of psoriasis, skin cancer, and other indications |
| MY194410A (en) | 2015-08-06 | 2022-11-30 | Coats Agri Aloe Llc | Compositions and Methods to Increase Plant Yield |
| GB201620701D0 (en) * | 2016-12-06 | 2017-01-18 | Glaxosmithkline Consumer Healthcare (Uk) Ip Ltd | Novel composition |
| WO2018191505A1 (en) * | 2017-04-12 | 2018-10-18 | Performance Labs PTE. LTD. | Production of aspirin-triggered resolvins without the use of aspirin in a dietary omega-3 supplement |
| CN110870914A (zh) * | 2018-08-31 | 2020-03-10 | 成都夸常奥普医疗科技有限公司 | 氨基酸类营养素的应用以及包含它的药物组合物 |
| JP7642955B2 (ja) * | 2021-02-04 | 2025-03-11 | 株式会社ファンケル | 嗅覚受容体発現促進用組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5940M (OSRAM) * | 1966-10-18 | 1968-04-08 | ||
| FR2602678B1 (fr) * | 1986-08-13 | 1992-06-05 | Drouault Guy | Composition pharmaceutique aqueuse a base de sels de magnesium, sodium et potassium pour la regulation des circulations locales |
| DK0424028T3 (da) * | 1989-10-17 | 1996-01-29 | Merck & Co Inc | S(+)-ibuprofen-L-aminosyre og S(+)-ibuprofen-D-aminosyre som et forbedret smertestillende middel med fremskyndet indtrædelse |
| JPH045231A (ja) * | 1990-04-20 | 1992-01-09 | Morishita Pharmaceut Co Ltd | 慢性痛用鎮痛剤 |
| JPH0789862A (ja) * | 1990-05-29 | 1995-04-04 | Toyobo Co Ltd | 抗炎症性、免疫抑制性および鎮痛性組成物、およびこれらの組成物を用いた自己免疫疾患の治療方法 |
| DE4100975A1 (de) * | 1991-01-15 | 1992-07-16 | Weuffen Wolfgang | Kosmetische oder pharmazeutische zubereitungen zur verbesserung der haarqualitaet und foerderung des haarwachstums |
| US5852058A (en) * | 1993-06-11 | 1998-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury |
| DE4338793A1 (de) * | 1993-11-12 | 1995-05-18 | Froelich Juergen C | L-Arginin und Analoge als Thrombozytenaggregationshemmer |
| DE4341000A1 (de) * | 1993-12-02 | 1995-06-08 | Beiersdorf Ag | Verwendung von L-Arginin, L-Ornithin oder L-Citrullin und topischen Zubereitungen mit diesen Stoffen |
| US5594032A (en) * | 1994-11-10 | 1997-01-14 | Gonzalez-Cadavid; Nestor F. | Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA |
| US5595753A (en) * | 1995-04-14 | 1997-01-21 | President And Fellows Of Harvard College | Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract |
| US5734080A (en) * | 1995-09-22 | 1998-03-31 | Anihealth Corporation | Reaction product of arginine and p-aminobenzoic acid, cosmetic, and human and animal health compositions thereof |
-
1998
- 1998-09-17 DE DE69841481T patent/DE69841481D1/de not_active Expired - Lifetime
- 1998-09-17 AT AT98946099T patent/ATE456302T1/de not_active IP Right Cessation
- 1998-09-17 ES ES98946099T patent/ES2340450T3/es not_active Expired - Lifetime
- 1998-09-17 JP JP2000511359A patent/JP4352114B2/ja not_active Expired - Fee Related
- 1998-09-17 EP EP09014985.7A patent/EP2158907B1/en not_active Expired - Lifetime
- 1998-09-17 WO PCT/US1998/019429 patent/WO1999013717A1/en not_active Ceased
- 1998-09-17 AU AU93186/98A patent/AU737199B2/en not_active Ceased
- 1998-09-17 CA CA2303394A patent/CA2303394C/en not_active Expired - Fee Related
- 1998-09-17 ES ES09014985.7T patent/ES2549329T3/es not_active Expired - Lifetime
- 1998-09-17 EP EP98946099A patent/EP1041880B1/en not_active Expired - Lifetime
-
2009
- 2009-03-31 JP JP2009084491A patent/JP2009143968A/ja active Pending
-
2014
- 2014-10-07 JP JP2014206221A patent/JP2015038119A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015038119A (ja) | 2015-02-26 |
| AU9318698A (en) | 1999-04-05 |
| DE69841481D1 (de) | 2010-03-18 |
| JP2009143968A (ja) | 2009-07-02 |
| WO1999013717A1 (en) | 1999-03-25 |
| WO1999013717B1 (en) | 1999-04-22 |
| CA2303394C (en) | 2011-12-20 |
| EP1041880B1 (en) | 2010-01-27 |
| JP4352114B2 (ja) | 2009-10-28 |
| EP2158907A2 (en) | 2010-03-03 |
| CA2303394A1 (en) | 1999-03-25 |
| ES2549329T3 (es) | 2015-10-27 |
| EP2158907A3 (en) | 2010-05-26 |
| EP1041880A4 (en) | 2006-04-12 |
| EP2158907B1 (en) | 2015-08-05 |
| AU737199B2 (en) | 2001-08-09 |
| EP1041880A1 (en) | 2000-10-11 |
| ATE456302T1 (de) | 2010-02-15 |
| JP2002515401A (ja) | 2002-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1041880B1 (en) | Administration of arginine to warm cool/cold tissue | |
| ES2429443T3 (es) | Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada | |
| US6207713B1 (en) | Topical and oral delivery of arginine to cause beneficial effects | |
| ES2234091T3 (es) | Preparacion para la piel. | |
| ES2421142T3 (es) | Administración tópica de un donante de óxido nítrico para mejorar el aspecto corporal y de la piel | |
| JP2002515401A5 (OSRAM) | ||
| US20030028169A1 (en) | Topical delivery of L-arginine to cause beneficial effects | |
| US20130210921A1 (en) | Method for Giving Warmth to Skin | |
| US20130289059A1 (en) | Beneficial effects of increasing local blood flow | |
| ES2295071T3 (es) | Compuestos estimulantes de los tejidos para mujeres y metodo y aparato para la administracion de estos compuestos. | |
| ES2562494T3 (es) | Composiciones estabilizadas para administración tópica y métodos para preparar las mismas | |
| ES2605644T3 (es) | Composiciones y método para la estimulación de la respuesta sexual femenina y masculina | |
| ES2314365T3 (es) | Utilizacion de una composicion que comprende oxido de vitamina k1 o un derivado del mismo para el tratamiento y/o la prevencion de lesiones dermatologicas en los mamiferos. | |
| ES2360706T3 (es) | Utilización cosméticda o terapéutica de toxina botulínica para prevenir el crecimiento del pelo. | |
| ES2236899T3 (es) | Utilizacion de acido tioglicolico como agente despigmentante. | |
| WO1995023580A1 (en) | Preventive and remedy for secondary depilation | |
| RU2216314C1 (ru) | Крем-маска для обезвоженной кожи | |
| CA2835840C (en) | Beneficial effects of increasing local blood flow | |
| HK1188943A (en) | Transdermal delivery of beneficial substances effected by a hostile biophysical environment | |
| BRPI0405212B1 (pt) | Processo criogênico de incorporação de ingredientes ao gelo, pré-embalagem para acondicionar o gelo assim formado, processo de preparação de um produto crioterápico, uso e método de aplicação do gelo e do produto crioterápico | |
| WO2014080051A1 (es) | Uso de la l-carnitina en productos cosméticos dermatológicos para el tratamiento de estrías y cicatrices |